Healthcare technology investor NetScientific PLC (LON:NSCI) has alerted shareholders to the formation of a scientific advisory board at its diagnostics portfolio company, ProAxsis.
The advisory board will support ProAxsis in the development of its Proteasetag activity-based immunoassays and point-of-care tests, including those designed for the detection and measurement of active Neutrophil Elastase.
"ProAxsis's ProteaseTag tests have the potential to greatly improve the routine monitoring of patients with serious chronic diseases such as cystic fibrosis and COPD,” observed Francois Martelet, NetScientific's chief executive officer.
“In bringing together this hugely respected group of clinicians specialising in CF [cystic fibrosis] and respiratory diseases, ProAxsis will ensure it has world class guidance as it continues to realise this potential," Martelet added.